CORNING, N.Y. (WENY) — The Johnson and Johnson vaccine is currently under review by the FDA, which means a third COVID-19 vaccine could be approved and ready to roll-out in less than a month.

With two different COVID-19 vaccines already being put into arms, it might be tempting to compare them to any new vaccines, but Mark Hopson, director of pharmacy at Guthrie Corning Hospital, says comparing Johnson and Johnson to Pfizer or Moderna isn't the same as comparing apples to apples.

"This vaccine is a different type of vaccine, it's not a Messenger RNA vaccine. It is an adenovirus-based vaccine, which is a more traditional platform that we've had experience with making other vaccines for other viruses."

Though all three vaccines offer immunity to COVID-19, Hopson says each company had a different focus during the vaccine trials.

"The J&J trial was looking for a reduction in moderate to severe symptoms of COVID. Whereas Moderna and Pfizer looked at all levels."

When it comes to how effective a vaccine needs to be, Hopson says companies like Pfizer and Moderna raised the bar much higher than health officials expected.

"Keeping in mind that when we first started developing vaccines, the world health organization was looking at a 50 percent effective level for the vaccine. That would be considered effective," Hopson said.

According to Hopson, hospitals could have an easier time managing this vaccine.

"One of the advantages of the J&J vaccine is that it's stable for up to 3 months in a refrigerator. This makes it easier for doctors' offices or pharmacies to store this vaccine and not have it expire."

Johnson and Johson is in the process of starting a two-dose trial in hopes of achieving a higher level of immunity. Hopson says this could offer more immunity to COVID-19 variants.

If the Johnson and Johnson vaccine is approved by the FDA, health officials expect distribution to ramp-up significantly.

"From what I understand, J&J has the ability to distribute 100 million doses, which has been purchased by the federal government, by the end of June," Hopson said.

Including the U.S., Johnson and Johnson conducted trials in 8 different countries. If the vaccine gets emergency use authorization, the company says they could produce as many as one billion vaccines for world-wide use by the end of 2021.